Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (December 2020)
28 slides from Rhythm Biosciences's investor presentation, Dec 21, 2020
Slide 1: A transformative, predictive cancer diagnostics technology company
A transformative, predictive cancer diagnostics technology company Initial Product Aim = ColoSTAT® the early detection of colorectal cancer using a simple, accurate & low-cost blood test, designed for global mass-market screening. Investor Presentation 21 December 2020 ASX: RHY © Rhythm Biosciences
Slide 2: Important Notice
Important Notice • This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations o
Slide 3: Corporate Overview
Corporate Overview Rhythm Biosciences (ASX: RHY) Financial Information ASX Code: RHY A transformative, predictive cancer Share Price (18 December 2020) $0.805 diagnostics technology company 12-Month Range $0.041 - $0.95 ✓ RHY is a new-generation / disruptive Shares on Issue ~201.496m cancer diagnost
Slide 4: Board and Management
Board and Management A strong and industry experienced board and management team, with a pedigree of building successful businesses. OTTO BUTTULA GLENN GILBERT TREVOR LOCKETT LOU PANACCIO DAVID WHITE EDUARDO VOM Chief Executive Technical – Non-Executive Non-Executive Non-Executive Chairman Officer E
Slide 5: Key Investment Highlights
Key Investment Highlights As a simple, accurate & low-cost blood test, Rhythm’s ColoSTAT® has potential to substantially increase global mass market screening ✓ Transformative Diagnostic Company: Focused on early detection of colorectal cancer (CRC) using a simple, low-cost blood test that could rev
Slide 6: Key Investment Highlights
Key Investment Highlights As a simple, accurate & low-cost blood test, Rhythm’s ColoSTAT® has potential to substantially increase global mass market screening ✓ Sound technology: 13 years of R&D pioneered by CSIRO^ combined with 3 years RHY, giving confidence in the biomarkers selected. ✓ Key Lead B
Slide 7: Colorectal Cancer – Mass-Market Screening Is Critical
Colorectal Cancer – Mass-Market Screening Is Critical Colorectal cancer is the second largest cause of cancer-related deaths in the industrialised world with over 850,000 deaths annually. Curable in over 90% of cases if detected early. This drops to circa 10% if detected late and once the cancer has
Slide 8: Late-Stage Bowel Cancer Treatment Costs Are Increasing
Late-Stage Bowel Cancer Treatment Costs Are Increasing Early detection is the key to survival and reducing the healthcare burden $100,000 $66,000 $71,156 per patient per patient1 per patient2 & rising3 (2012-13) (2016) (2016) ColoSTAT® is expected to deliver a significant cost / benefit factor to as
Slide 9: ColoSTAT® - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? A simple, accurate, low cost blood test for the early detection of colorectal cancer designed for the global mass market ➢ Detects protein biomarkers in the blood that are indicative of an increased likelihood of presence of colorectal cancer. (accurate) ➢ B
Slide 10: ColoSTAT® - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? A simple, accurate, low cost blood test for the early detection of colorectal cancer designed for the global mass market Serum ColoSTAT® ColoSTAT® preparation Immunoassays Algorithm Routine blood Diagnostic Standard lab processes collection report Technology
Slide 11: Current FIT Pathway - Cumbersome And Not Well Adopted
Current FIT Pathway - Cumbersome And Not Well Adopted FIT Testing Central FIT Sample Pathology Collection lab Process Diagnostic assessment to GP * ➢ Multi step faecal collection, packaging over at least 2 days then posting sample back to a central laboratory. Obligation on patient to sample and lab
Slide 12: ColoSTAT® - Patient Friendly - Increased Compliance
ColoSTAT® - Patient Friendly - Increased Compliance “83% of unscreened participants preferred a blood test over a faecal test” * Simple & Routine Patient Journey With ColoSTAT® GP referral Any Routine blood draw Pathology lab Diagnostic assessment to GP ✓ColoSTAT® - has the potential to increase scr
Slide 13: ColoSTAT®'s - Competitive Advantage
ColoSTAT®’s - Competitive Advantage Rhythm Faecal Immunochemical Test (FIT) Patient Preference Patient Preference Accuracy Accuracy Early Stage Detection Early Stage Detection Affordability Affordability Simple Process Simple Process Opportunistic Screening* Opportunistic Screening* ColoSTAT®’s comb
Slide 14: ColoSTAT® - Development History
ColoSTAT® - Development History • ColoSTAT® relies on detecting biomarkers in blood that indicate an increased likelihood of presence of colorectal cancer. • For over 13 years CSIRO investigated over 68 potential biomarkers until a panel of 10 lead targets remained, using individually sourced commer
Slide 15: Clinical Trial (Study 7) – Performance In A Clinical Setting
Clinical Trial (Study 7) – Performance In A Clinical Setting Trial Study Design End Points Key Recruitment Challenge: Prospective, Cross sectional, Primary: multicentre clinical trial. Performance of ColoSTAT® for ➢ Hospitals maintaining motivated key detection of CRC relative to trial staff members
Slide 16: Study 7 – New Trial Sites Motivated To Recruit
Study 7 – New Trial Sites Motivated To Recruit “The burden of colorectal cancer and the benefits of early detection have been well recognised. The risk of colorectal cancer increases dramatically over 50 years of age, yet the majority of people in this age group remain unscreened. A blood-based diag
Slide 17: Confidence In Performance Moving Forward
Confidence In Performance Moving Forward ✓ ColoSTAT® prototype test-kit complete using Rhythm’s proprietary algorithm that continue to improve. ✓ Preliminary results from the prototype test-kit outperform current market standard (faecal test) and previous CSIRO test work. ✓ CE Mark application may b
Slide 18: Key Achievements - Delivered In 2020
Key Achievements - Delivered In 2020 ✓ Technically validated the key lead and four adjunct biomarkers. ✓ Appointed additional clinical trial (Study 7) sites. ✓ ISO13485 Quality Management System certification maintained. ✓ Completed reagent development program. ✓ Commenced high-volume manufacturer s
Slide 19: Key Achievements - ColoSTAT® Performance
Key Achievements - ColoSTAT® Performance Prototype test-kit results outperform current global market standard Sensitivity is the ability of the test to correctly identify those patients with colorectal cancer, that is, the percentage of people with colorectal cancer who are correctly identified as h
Slide 20: Market Opportunity – Global Screening Numbers
Market Opportunity – Global Screening Numbers Screening compliance & opportunity by market Europe (incl UK) China 19 % 38 % 63 50-74 population Japan 38 USA % 396.6M % 50-74 population 231.2M 321.2M 50-74 population unscreened 50-74 population 93.6M 41.5M 143.4M unscreened 34.7M 25.7M unscreened uns
Slide 21: Market Likely To Expand Significantly
Market Likely To Expand Significantly Colorectal Cancer is also prevalent in younger segments of the population ✓ Colorectal cancer is the leading cause of cancer related deaths for 30-to-35-year-olds in both males and females in Australia. ✓ It is also the leading cause of cancer related deaths for
Slide 22: Where Could ColoSTAT® Value Be Derived From
Where Could ColoSTAT ® Value Be Derived From Who are the potential Simplified Value Story payers? Government – ColoSTAT® National Screening Program Because the vast majority of patients prefer a blood Government – Increased CRC screening rates test vs tests involving faecal handling National/Regiona
Slide 23: Potential ColoSTAT® Total Market Size (50-74yr old only)
Potential ColoSTAT ® Total Market Size (50-74yr old only) $4.68bn $11.56bn $336.5m $19.83bn $2.08bn (Patient/market share 50-74-year olds) Market Penetration 75% $3.51bn $8.67bn $252.4m $14.87bn $1.56bn $28.86bn 50% $2.34bn $5.78bn $168.2m $9.91bn $1.04bn $19.24bn 25% $1.17bn $2.89bn $84.13m $4.96bn
Slide 24: Go To Market Options
Go To Market Options Multiple avenues and market segments reduce risk and support a flexible and scalable business model National Screening Program/MBS Reimbursed Secondary Triage National • With its effectiveness and Screening Triage • As a transition, ColoSTAT® could be used as a follow affordabil
Slide 25: Competitive Landscape – ColoSTAT®'s Unique Advantage
Competitive Landscape – ColoSTAT®’s Unique Advantage Blood based Epigenomics Volition Rx Rhythm Novigenix Epi proColon® ColoSTAT® Colox® Nu.q™ ~$300 per test ~$104m ~$250 per ~$150 per test test ~$80m ~$152m private Clinical Genomics Colvera™ ~$400 per test private ColoSTAT®’s comparative low cost &
Slide 26: IP – Patents Filed In All Major Target Markets
IP – Patents Filed In All Major Target Markets Granted Pending ➢ Licensed from CSIRO United States France Brazil ➢ Worldwide exclusive licence Australia Germany India ➢ Patent wholly owned by Vision China (x2) Italy Tech Bio Pty Ltd* ➢ Expires 2031 Japan Luxembourg United Kingdom Netherlands ➢ Metho
Slide 27: Future Value Inflection Points – 2020-2021
Future Value Inflection Points – 2020-2021 With R&D significantly de-risked, anticipated near-term value inflection points on the path to towards commercialisation include: ➢ Further clinical trial sites to be appointed to accelerate recruitment. ➢ Complete design transfer of the ColoSTAT® prototype
Slide 28: Thank you
Glenn Gilbert CEO, Rhythm Biosciences glenn.gilbert@rhythmbio.com +61 3 8256 2880 Thank you www.rhythmbio.com © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL 28
Rhythm Biosciences — Investor Presentation (December 2020) on 6ix